Introduction
Cancer is a leading cause of burden of disease globally 1 and is responsible for approximately three in 10 deaths. 2 However, with improved screening and advancing treatment options, survival rates are improving. As a result, cancer is now recognised as a chronic disease. 3, 4 While treatment may improve survival, the side-effects on physical and psychological function often reduce quality of life. There is an increasing need for rehabilitation to address these issues. Exercise is an effective treatment for many chronic diseases. Recent systematic reviews have demonstrated that exercise used as part of cancer care reduces cancer-related fatigue and improves cardiovascular function, strength and quality of life. [5] [6] [7] [8] [9] There is also emerging evidence that exercise can reduce recurrence and mortality in some cancer populations. [10] [11] [12] [13] [14] [15] [16] Despite these benefits of exercise, there is a lack of evidence on the safety and efficacy of exercise in relation to dose. 6, 17 The ideal mode and intensity of exercise for people with cancer is unclear, and exercise guidelines are based largely on expert clinical opinion and adaptations of guidelines for healthy people. Current recommendations suggest that cancer survivors complete at least 150 minutes of moderate-intensity physical activity per week. 6 However, these recommendations may not recognise the specific health needs of cancer survivors. Recent reviews have reported a low number of adverse events in relation to exercise trials, 6, 7, [18] [19] [20] suggesting that exercise is generally safe for cancer survivors. However, in these reviews, there has been variable reporting of the dose of prescribed exercise. The association between inflammation and cancer is well documented. [21] [22] [23] Chronic inflammation plays a role in the pathogenesis of insulin resistance and tumour growth, and has been linked to cancer risk and mortality. [23] [24] [25] [26] Inflammatory cytokines have also been implicated in the development of cancer-related fatigue. [27] [28] [29] Exercise plays a role in mediating markers such as C-reactive protein (CRP), tumour necrosis factoralpha, and various types of interleukin (IL), including IL6, in people with and without cancer. [30] [31] [32] Furthermore, the protective effects of exercise have been attributed to the creation of an antiinflammatory environment through increasing anti-inflammatory cytokines such as ILRa and IL10 in healthy people. 26, 33, 34 The relationship between exercise dose and inflammatory markers in people with cancer needs to be considered because strenuous exercise can induce pro-inflammatory cytokines in healthy people. 35 Therefore, it is important to know how much exercise can be safely tolerated in this immune-compromised population of people with cancer. Cancer-related fatigue affects 80 to 100% of patients. 36 Fatigue is a complex multi-dimensional construct related to reduced physical function and reduced health-related quality of life. 27, 37 Recent reviews have concluded that exercise reduces cancerrelated fatigue, 19, [38] [39] [40] but the optimal dose to achieve this has not been established. It has been suggested that patients undergoing treatment may need to exercise at a lower intensity or for a shorter duration than those who have completed primary treatment. 41 However, others have suggested that higher-intensity exercise may be better. 42, 43 For example, Brown et al 40 found that moderate-intensity resistance exercise may be more effective than low-intensity exercise for reducing cancer-related fatigue.
The most effective duration and intensity of exercise remain unclear. Therefore, the research questions that we sought to answer with this systematic review were:
1. Is there a dose-response effect of exercise on inflammation and fatigue in adult cancer survivors? 2. Is there a dose-response effect of exercise for improving functional activity in this population?
Method
This systematic review was reported in accordance with PRISMA guidelines. 44 , 45 
Search strategy
The Medline, EMBASE and CINAHL databases were searched from the earliest records to April 2015. PubMed was also searched from 2010 for more recent publications. The search strategy was based around synonyms and MeSH subject headings of the key concepts of exercise and cancer combined with the primary outcomes of fatigue and inflammation. These terms were combined with relevant filters to identify randomised, controlled trials. 46 The detailed search strategy is presented in Appendix 1 (see eAddenda). The database searches were supplemented by citation tracking of included articles using Google Scholar and checking the reference lists of included studies.
Eligibility criteria
The eligibility of papers identified by the searches was assessed by two reviewers who independently considered information from the titles and abstracts against predetermined eligibility criteria (Box 1). Disagreements were resolved by discussion, with a third reviewer consulted when necessary. Where eligibility was unclear from the title and abstract, the full-text version was obtained and examined by both reviewers.
To be included, studies had to be randomised, controlled trials that: examined the effect of exercise in adults who had been diagnosed with cancer, reported at least one of the primary outcomes (fatigue or inflammation) and were published in English. The exercise intervention had to meet the definition 'physical activity that is planned, structured and repetitive and has a final or intermediate objective of the improvement or maintenance of physical fitness' 47 with aerobic or resistance training as a key component, because these modes of exercise are expected to result in significant physiological changes that may affect inflammation and fatigue, and are quantifiable. Furthermore, the intensity (eg, percentage of maximum heart rate, repetition maximum, etc) or duration of completed exercise needed to be reported. For studies using a combined exercise intervention (ie, aerobic and resistance training), the intensity or total duration for both components must have been specified. Studies were excluded if only a single bout of exercise was used or if it was combined with a co-intervention such as diet or education.
Quality assessment
The studies were assessed by two reviewers, who independently rated the 11 criteria on the PEDro scale as yes or no. One criterion relates to external validity; the remaining 10 criteria contribute 1 point each, if met, to give a score out of 10. The PEDro score is a valid measure of internal validity and completeness of reporting. It has undergone Rasch analysis and has moderate levels of inter-rater reliability (ICC 0.68, 95% CI 0.57 to 0.76). 48, 49 Trials scoring < 6 were deemed to be of low quality. 50 
Synthesis of results
A standardised mean difference (SMD) was calculated for each outcome from post-intervention means and SDs to compare the control and treatment groups and to account for different scales of measurement between studies. Where only change scores were reported, the post-intervention mean was estimated in reference to the baseline mean and the SD based on baseline data. If only a range was given, the SD was calculated. 51 Authors were contacted if there was insufficient published data for analysis. Data from outcome measures were classified into three categories to address the primary and secondary aims of the review: inflammation, fatigue and activity. Activity was defined according to the World Health Organization International Classification of Functioning as 'the execution of a task or action by an individual', which included measures of activities of daily living and functional mobility. 52 Meta-analysis was completed using the R statistics package 'metafor' 53 to provide evidence of the pooled effect size of the exercise intervention. Data were combined if clinically homogenous for more than two trials. Random effects models and a restricted maximum likelihood estimator for the random effect variance parameter were used. 54 A meta-analysis of the ratio of sample variances 55 provided evidence of unequal variances Box 1. Inclusion criteria.
Design

Randomised trial Published in English
Participants
Adults with cancer
Intervention Exercise intervention with aerobic or resistance exercise as a key component Sufficient reporting of dose (ie, the intensity or duration must be reported). For combined modalities, the intensity or total duration for both components must be specified.
Outcome measures
Must report at least one measure of fatigue or inflammation
Comparisons
Exercise versus control Exercise plus usual care versus usual care only One exercise dose compared to another (eg, high versus low intensity)
between the control and treatment groups. Consequently, Glass' D 56 was employed where the difference in means was standardised using the control-group sample SD. Subgroup analyses were completed to determine the effect of tumour stream, treatment status and exercise modality. The Grades of Research, Assessment, Development and Evaluation (GRADE) approach was applied to each meta-analysis to evaluate the evidence across trials. 57 The approach involved downgrading the evaluation based on these predetermined criteria: the PEDro score was < 6 for the majority of trials used in the meta-analysis; there was greater than low levels of statistical heterogeneity between trials (I 2 > 25%); there were large confidence intervals (ie, > 0.8 SMD); and if there was asymmetry of a funnel plot when more than 10 trials were included in the meta-analysis, demonstrating evidence of publication bias. Meta-regression analysis assessed the pooled dose-response relationship between exercise dose and outcomes. To standardise dose for analysis, duration of exercise per week and intensity were evaluated separately, with intensity quantified as maximum oxygen consumption (VO 2max ) or a percentage of one repetition maximum (1RM). Meta-regression models were fitted to both factor and numeric variables to obtain subgroup estimates (for the factor variables) and estimated increases in effect sizes for oneunit changes of numeric covariates. Analysing exercise dose by volume in metabolic equivalents (METs)/minute/week was considered; however, there were inadequate data. Exercise intensity was categorised as low (< 40% VO 2max , < 60% 1RM), moderate (40 to 60% VO 2max , 60 to 80% 1RM) or vigorous/high (> 60% VO 2max , > 80% 1RM). 58, 59 Where outcome data could not be included in the meta-analysis or meta-regression, results were summarised descriptively.
Results
Study selection
The electronic database search resulted in a yield of 874 articles, which was reduced to 677 after the duplicates were removed. Additional articles were identified through citation tracking (n = 2) and reference list scanning (n = 4). Eighty-two articles were obtained in full text and further assessment reduced the yield to 49 articles. There was good inter-rater agreement about eligibility based on title and abstract (k = 0.695) and full texts (k = 0.691). Fourteen articles reported data from seven trials; therefore, 42 trials were included for review (Figure 1 ).
Quality
The mean score of the included trials was 5.7 (SD 1.4) on the PEDro scale (Table 1) . Inter-rater agreement on quality criteria was very good (k = 0.848). Three trials 60-62 scored 8 on the PEDro scale, which was the highest possible score given the nature of the intervention that was studied, where it would be unfeasible to blind clinicians or participants. Less than half of the trials had blinding of assessment and concealed allocation.
Study characteristics
Participants
Data from 3816 participants were included. The majority of participants were female (70%), with a mean age of 55 years (SD 9) and a mean body mass index of 27 kg/m 2 . Solid tumours were investigated in 34 trials (81%), haematological cancers were investigated in four trials, [63] [64] [65] [66] with an additional four trials investigating a combination of solid and haematological cancers. [67] [68] [69] [70] Breast cancer was the most frequently reported (27 trials, 64%), 30, [60] [61] [62] followed by prostate cancer (14 trials, 24%). 85, 88, 90, 92, [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] Interventions were commonly completed during the treatment phase (30 trials, 71%), with 12 trials completed in the post-treatment phase ( • not a randomised trial (n = 10)
• co-intervention (n = 8)
• insufficient reporting of dose (n = 5)
• no measure of fatigue or inflammation (n = 3)
• inadequate control (n = 3)
• issues with group randomisation or analysis (n = 3)
• participants receiving end-of-life care (n = 1)
Papers found via search of databases (n = 874)
Papers found via reference lists or citation tracking (n = 6)
Records after duplicates removed (n = 683)
Trials included in review (n = 42)
Trials included in meta-analysis (n = 34)
Inadequate data for meta-analysis (n = 8)
Trials included in meta-regression (n = 31)
Inadequate data for meta-regression of inflammation (n = 3) Figure 1 . Flow of trials through the review.
resistance exercise, 65 to high intensity, 100% of peak workload as interval training for aerobic exercise 61, 82, 105 and 85% of 1RM for resistance exercise 97 (Table 3) . No trials implemented lowintensity exercise.
Adverse events and adherence
The exercise interventions appeared to be safe and well tolerated. reporting an adverse event, 19 of the 1888 exercise participants Cormie 2015
Courneya 2004 99 a
Courneya 2007 76 a
Fairey 2005 30 a
Gomez 2011 had adverse events. Of these, six participants withdrew from the trials because of adverse event(s), including: dizziness, fatigue, bone pain, chest pain, acute myocardial infarction, anaemia, dyspnoea and knee pain. The adverse events that did not affect exercise participation were back pain, lower limb pain, post-exercise discomfort and a fall at home that was unrelated to the intervention. A meta-analysis found moderate-quality evidence that exercise did not increase the risk of an adverse event compared with usual care and there was no difference between exercise modalities or intensities (Table 4) . Resistance NR HRmax = maximum heart rate, HR = heart rate, HRR = heart rate reserve, MET = metabolic equivalents, NR = not reported, RM repetition maximum, RPE = Rating of Perceived Exertion, VO 2max = maximum volume of oxygen consumption, VO 2peak = volume of oxygen consumption at peak exercise. a Reports data on some or all of the same participants as the study below. b With initial supervised instructional session. Effects of exercise on health outcomes: meta-analysis Fatigue Meta-analysis provided moderate-quality evidence that exercise had a positive effect on fatigue when compared with usual care (SMD 0.32, 95% CI 0.13 to 0.52) (Figure 2 , Table 5 ). When adjusting for tumour type in subgroup analyses, there was insufficient evidence to suggest that exercise was effective for haematological or mixed tumour types. There was strong evidence in favour of exercise with respect to solid tumours and those undergoing treatment (Table 6 ). With respect to mode of exercise, a combination of aerobic and resistance training provided the largest treatment effect, with smaller and similar estimated effects for aerobic and resistance exercise alone (Table 6 ). Further metaanalysis provided moderate-quality evidence that a reduction in fatigue was maintained up to 6 months after the intervention when compared with usual care (Table 5) . One trial was not included in the meta-analysis because it did not have a usual-care control group. 75 This trial found no differences in fatigue when comparing different exercise modalities and dose (with respect to duration).
Inflammation
A meta-analysis of five trials 30, 80, 83, 97, 100 provided high-quality evidence of a non-significant reduction in levels of plasma CRP following exercise when compared with usual care. A metaanalysis of four trials 79, 83, 90, 107 provided moderate-quality evidence that there was no significant difference in plasma IL6 levels; and meta-analysis of two trials 79, 107 provided moderate-quality evidence that there was no difference in IL8 or IL10 levels following exercise (Table 5) . Two trials that were not included in the meta-analysis due to insufficient data did not show a significant difference between IL6 levels 87 or any of the cytokines tested. 60 Another trial that was also not included in the meta-analysis due to insufficient data demonstrated a significant reduction in ILb and IL2 in the exercise group during chemotherapy, and a significant increase in IL8 levels during the exercise intervention compared with usual care. 82 
Activity
Of the included trials, 18 reported on outcomes of functional mobility and one reported on activities of daily living. A metaanalysis of 15 trials provided very low-quality evidence of improvement in walking endurance following exercise when compared with usual care (Table 5, Figure 3 ). Sensitivity analysis was completed because a single trial demonstrated a significantly larger effect than other trials. When this study was removed, there was still a moderate effect in favour of the intervention, with high levels of heterogeneity (61%), which was unable to be explained by the study characteristics. There was evidence that exercise had a significant effect on walking endurance for solid tumour types (Table 6) . Moderate-quality evidence of four trials demonstrated no difference in usual walking speed following exercise when compared with usual care. There was also no difference in sit-tostand or stair climbing ability (Table 5) . One trial found no differences in patient-reported activities of daily living when comparing combined exercise to usual care. 96 
Dose-response analysis: meta-regression
A total of 31 trials were included in a meta-regression analysis of the dose-response effect of intensity and duration of exercise programs on fatigue and walking endurance.
Meta-regression analysis demonstrated a significant effect of exercise intensity on fatigue. Aerobic exercise intensity was negatively associated with treatment effect using linear regression models. For every 1% increase in intensity (from moderate to high) there was an estimated reduction of SMD 0.029 (95% CI 0.001 to 0.056) in the positive effect of exercise on fatigue (Figure 4 , top panel, solid line). However, there was no evidence of this for the aerobic exercise component of the combined exercise studies (estimated reduction per 1% increase SMD 0.005 (95% CI -0.038 to 0.048) (Figure 4, top panel, dotted line) . With respect to resistance intensity ( Figure 4 , bottom panel) and exercise duration (Figure 5 ), the meta-regression analyses did not detect any significant associations.
For walking endurance, only the intensity of aerobic exercise was analysed using data from the aerobic and the aerobic component of combined intervention trials. A quadratic metaregression model demonstrated that moderate-intensity aerobic exercise (70% relative intensity) led to a peak effect ( Figure 6 ). This association was close to significant. There was no association detected for exercise duration (Figure 7) . Meta-regression analysis was not completed for markers of inflammation because there were insufficient data. All studies measuring CRP and IL6 levels were moderate-intensity exercise.
[ ( F i g u r e _ 2 ) T D $ F I G ] Figure 2 . SMD (95% CI) of effect of exercise compared with usual care, on fatigue by pooling data from 33 trials with subgroup analysis by tumour type (haematological, mixed, solid), treatment phase (post-treatment, during treatment) and exercise modality (aerobic, combined aerobic and resistance, resistance). a Courneya et al. 77 .
Discussion
This systematic review provided moderate-quality evidence that exercise reduces fatigue in cancer survivors and very lowquality evidence that exercise improves walking endurance in this group. It also provided evidence of a negative dose-response relationship of aerobic exercise intensity and fatigue, and of a peak treatment effect of moderate-intensity aerobic exercise for improving walking endurance. No significant dose-response was evident for the duration of weekly exercise. There was also moderate-quality to high-quality evidence that there is no significant difference in inflammatory markers after completion of an exercise program compared with usual care and no significant difference in usual walking-speed, sit-to-stand ability or stair climbing ability.
These findings support previous meta-analyses 7, 18, [38] [39] [40] suggesting that exercise can play a significant role in reducing fatigue, particularly in people with solid tumours. Consistent with previous evidence, these effects may not be generalisable to haematological cancers. 38, 40 Patients with haematological malignancies can experience many complications during treatment, including muscle atrophy, cachexia, anaemia, physical deconditioning and psychological distress. 64, 108, 109 In particular, anaemia has been shown to affect people with haematological cancers more than those with solid tumours 110 and this is a known contributor to cancer-related fatigue. 27 Therefore, this complication may be less able to be resolved through exercise. Our review also demonstrated a significant effect of exercise in reducing fatigue in people undergoing treatment, but not after treatment. A possible explanation could be a ceiling effect 70, 73, 88, 91, 101 were rated lower quality, evidence of publication bias. e Reason for downgrade: heterogeneity, all trials were rated lower quality, without blinded outcome measures and allocation concealment, wide confidence intervals. f Reason for downgrade: heterogeneity, evidence of publication bias. g Reason for downgrade: heterogeneity, four trials were rated lower quality 63, 91, 94, 104 , wide confidence intervals. h Reason for downgrade: heterogeneity, one trial was rated lower quality 94 , without blinded outcome measures and allocation concealment, wide confidence intervals. occurring after treatment, when fatigue may be less severe. Previously, reductions in fatigue were not found to be maintained after completion of the exercise program. 19, 40 However, in this review, reduction in fatigue was maintained at follow-up. This may be explained by a larger number of studies that included a specified exercise dose, which is important because people need to exercise with sufficient duration and intensity to be able to induce longterm physiological change to their health. The significant reductions in fatigue were accompanied by significant improvements in walking endurance. It has been hypothesised that the physical dimension of fatigue has an organic cause. 111 Cancer survivors have low physical activity levels, 112 which in turn reduce physical performance and impair skeletal muscle function and cardiovascular fitness. This cycle of deconditioning, which perpetuates fatigue, can be broken through the physical adaptations of exercise training. Exercise may also provide the additional benefits of improved mood and reduced anxiety and fear, which are known contributors of cancer-related fatigue. 111, 113, 114 The safety of exercise in people with cancer was re-enforced by this review, and evidenced by a low number of adverse events and a non-significant reduction in the inflammatory marker CRP. There was also no difference in the levels of the interleukins assessed. These inflammatory markers have previously been linked to tumour development and recurrence, as well as contributing to the development of fatigue. The results in this review suggest that exercise does not increase any pro-inflammatory markers, which contribute to cancer risk and tumour development.
Moderate-intensity exercise has a greater effect on reducing fatigue and increasing walking endurance than high-intensity exercise. This is a plausible outcome, given the nature of the mechanism of physiological changes as a result of exercise. Regular exercise induces stress on the cardiovascular and muscular systems in order for physical adaptation to occur. 115 However, in people with cancer, baseline exercise tolerance is reduced secondary to the effects of disease and treatment-related factors. Some tumours may directly disrupt pulmonary mechanics and may also be accompanied by side effects such as weight loss, anaemia and muscle wasting. 116 Treatment such as chemotherapy and radiotherapy can further exacerbate issues with oxygen delivery by inducing pulmonary and cardiovascular damage as well as increasing inflammation and reactive oxygen species; such changes are correlated with change in myocardial strain. 111, 116 Therefore, while physical activity is important to relieve fatigue, a balance in the amount of physical activity is also required. However, it should be considered that other training factors such as interval period, duration and length of the program might [ ( F i g u r e _ 3 ) T D $ F I G ] influence the effectiveness of high-intensity training, which this review was unable to assess. It should also be noted that there were no trials included in this review that assessed low-intensity exercise. So, while there is evidence that moderate-intensity exercise may reduce fatigue and improve mobility more effectively than high-intensity, it cannot be concluded that moderateintensity exercise is superior to low-intensity exercise for improving these outcomes. A dose-response relationship for exercise in relation to inflammatory markers was unable to be established. Previous literature has suggested that inflammatory biomarkers' response to exercise is dependent on the volume of mechanical work completed. 117 There were too few trials to establish a doseresponse relationship and a lack of variation in exercise intensity levels in the trials that measured inflammation. There is evidence that high-intensity or prolonged exercise duration can cause immune suppression and increase susceptibility to infection in healthy people. 115 This is a major consideration, given that people with cancer are often immunocompromised. The current recommendations for exercise for people with cancer are that they complete at least 150 minutes of moderateintensity exercise per week. 6 It is also recommended that people with cancer complete a combination of aerobic and resistance exercise to achieve this goal. Results from this review support the recommendation to complete moderate-intensity exercise, particularly in relation to aerobic exercise and the benefits of combined aerobic and resistance exercise programs for improving cancerrelated fatigue. 19, [38] [39] [40] The recommendation for the amount of exercise required to achieve benefits for fatigue and activity is less clear. As such, cancer survivors should follow the recommendation
[ ( F i g u r e _ 6 ) T D $ F I G ] Figure 6 . Meta-regression scatter plot of 12 trials showing the relationship between aerobic exercise intensity (% relative intensity) and the effect on walking endurance (effect size, 95% CI), fitted with quadratic regression line.
[ ( F i g u r e _ 5 ) T D $ F I G ] to avoid inactivity 6 and complete as much moderate-intensity exercise as tolerated. It is believed that this was the first review that analysed the effect of dose on fatigue in cancer survivors using meta-regression analysis across exercise modalities. It was also the first to investigate the effects of exercise on inflammatory biomarkers in people with cancer using meta-analysis. It included only randomised, controlled trials, which reduced the risk of selection bias and increased confidence in the results.
There were some limitations to this review. The search strategy included only four databases and was restricted to the English language, which posed some risk of publication bias. However, relatively few articles were located through additional methods and forest plots were analysed for publication bias. The results for activity outcomes were based on trials where fatigue and/or inflammation were also measured among the outcomes, so the results for activity may not be based on a complete set of available trials. However, previous reviews on exercise interventions for adults with cancer have reported similar results in relation to activity outcomes such as walking endurance. 5, 7 The overall quality of the evidence was moderate to high, but there were high levels of unexplained heterogeneity in the meta-analyses; this is consistent with previous meta-analyses. 5, 19, [38] [39] [40] This may have limited the confidence in the size of the pooled effect. To account for this, subgroup and sensitivity analyses were completed based on tumour stream and treatment phase. There was also evidence of unequal variances between groups, which influence the way in which the differences of means should be standardised; Glass' D effect size was used to overcome this. The analyses were also conducted using Cohen's d and the main findings remained intact. Combining a number of relative-intensity measures (eg, maximum heart rate, VO 2max and Borg) may also be a limitation. However, since these are effective measures of intensity and standardised effects were used, this was unlikely to be an issue.
In conclusion, this review of 42 randomised, controlled trials supports the growing body of evidence that exercise is a safe and effective intervention for reducing fatigue and improving mobility in adult cancer survivors. It was also able to establish a doseresponse relationship of intensity for aerobic exercise, supporting current recommendations emphasising moderate-intensity aerobic training in exercise programs for cancer survivors. These findings demonstrated greatest effect in people with solid tumours, with no significant effect evident for people with haematological malignancies.
What is already known on this topic: For people with cancer, exercise has beneficial effects on strength, cardiovascular function, fatigue and quality of life. However, the ideal mode and intensity of exercise for people with cancer is unclear. What this study adds: Exercise is safe and reduces fatigue and increases endurance in cancer survivors. Moderate-intensity exercise appears to be the most appropriate aerobic exercise for benefits on fatigue and walking endurance. 
